home

Epi-C’s goal is to modulate the complex mechanism of epigenetic regulation, forcing cancer cells to restore physiological activity and die either for senescence or programmed death – apoptosis .
In addition, since epigenetic mechanism(s) modulate both the induction and the interference with cell death, Epi-C’s molecules might be applied to degenerative diseases, as well as chronic, metabolic alterations.

Epi-C is a Drug-Agent

specialized in the discovery phase of new molecules

Epi-C (Epigenetic Compounds) is a new spin-off biotech company operating in the field of epigenetics. One of our primary aims is to develop novel drugs with anti-cancer properties.

Epi-C performs small molecule screenings, as well as bio logical and molecular characterisation of drugs.

Epi-C workflow

Epi-C workflow based on library high-throughput screening (HTS)
by automated equipment, data analysis, processing, Hit to lead Identification and Optimization.

epi-c method
epi-c method

Top Italian Scientists (TIS)
EpiGenetics Medicine

Lucia Altucci

MD, PhD

Full Professor of General Pathology, University of Campania Luigi Vanvitelli, IT. She is the scientific director of Epi-C and has more than 20 years of experience and more than 170 scientific publications on epigenetics to his credit.

SOME NUMBERS

DRUG SCREENING

High-throughput screen
of a large compound collection.

DRUG TESTING

Drug testing efficacy, reproducibility and specificity: 90-100%.

DRUG DISCOVERY

Hit identification success
80% during years.

PATENT OF DISCOVERED

Patent of Discovered
Lead compounds: 100%

Anticancer Research
JMJ KIT - KDM4A
Inhibitor Enzymatic
Assay Kit

EPI-C TIMELINE

PARTNERS